Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03333031 · ClinicalTrials.gov registry record · Phase 1
A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies
A Phase 1 study, sponsored by Herbert Lyerly.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03333031: Clinical Trial Phase 1 study, sponsored by Herbert Lyerly.
NCT03333031 is a Phase 1 study that was terminated before completion, run by Herbert Lyerly. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03333031, a Phase 1 study, was terminated before completion, sponsored by Herbert Lyerly.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
HS-196 is near infrared red (NIR)-tethered HSP90 inhibitor for clinical imaging of selective tumor binding. HS-196 consists of a HSP90 inhibitor that binds competitively to the Hsp90 ATP binding domain connected by a linker to a contrast agent (near infrared (NIR) dye) that can be used for imaging. HS-196 can freely enter tumor cells to selectively bind Hsp90. Due to the the NIR dye, HS-196 accumulation in the malignant cells allows for specific visualization of tumors within the body.
Primary Outcome
Ratio of tumor to normal tissue fluorescence
Interventions
- DRUG HS-196
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-08-10 |
| Est. Completion | 2022-09-07 |
| Phase | Phase 1 |
Why NCT03333031 stopped before completion
NCT03333031 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which HS-196 is the first listed.
NCT03333031 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03333031 about?
NCT03333031 is a clinical study titled "A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies". HS-196 is near infrared red (NIR)-tethered HSP90 inhibitor for clinical imaging of selective tumor binding. HS-196 consists of a HSP90 inhibitor that binds competitively to the Hsp90 ATP binding domain connected by a linker to a contrast agent (near infrared (NIR) dye) that can be used for imaging. ...
What is the current status of trial NCT03333031?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2018-08-10. Estimated completion is 2022-09-07.
What interventions are being tested in trial NCT03333031?
The interventions under investigation include: HS-196 (DRUG).
Who is sponsoring clinical trial NCT03333031?
This trial is sponsored by Herbert Lyerly, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03333031's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI